A cancer drug target is only truly validated by demonstrating that a given therapeutic agent is
clinically effective and acts through the target against which it was designed. Nevertheless, it …

Signatures guide drug choice | Nature Skip to main content Thank you for visiting nature.com.
You are using a browser version with limited support for CSS. To obtain the best experience, we …

An alarming number of papers from laboratories nominating new cancer drug targets
contain findings that cannot be reproduced by others or are simply not robust enough to …

Drug target validation: Hitting the target | Nature Skip to main content Thank you for visiting
nature.com. You are using a browser version with limited support for CSS. To obtain the best …

The large-scale genetic profiling of tumours can identify potentially actionable molecular
variants for which approved anticancer drugs are available,–. However, when patients with …

The emphasis in cancer drug development has shifted from cytotoxic, non-specific
chemotherapies to molecularly targeted, rationally designed drugs promising greater …

The deployment of molecular biomarkers that are indicative of sensitivity to tumor-targeted or
immune-targeted cancer therapies improves the outcome of individual patients and …

An enhanced understanding of the molecular pathology of disease gained from genomic
studies is facilitating the development of treatments that target discrete molecular subclasses …

Raise standards for preclinical cancer research | Nature Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …

There are, at present, ten times more anticancer drugs being tested in clinical trials than
there were 15 years ago. Many of the new classes of agents, however, are predicted to work …